Sterility and endotoxin testing answer different questions

“Sterile” and “low endotoxin” may appear side by side on a materials record, but they answer different questions. The distinction matters in peptide research: a cell assay may respond to trace bacterial material even when no living bacteria are recovered, while an endotoxin result says nothing about whether a sample contains viable microbes. Reading the two results correctly begins with understanding what each method is built to detect.

1. Two tests, two questions

A sterility test seeks viable microorganisms in the material sampled. Its culture conditions must let an organism grow before the test can reveal it. FDA notes that the method can detect only organisms present in the tested sample and capable of growing in the specified media. A negative result therefore has limits, especially when contamination is unevenly distributed.¹

A bacterial endotoxin test instead detects or quantifies lipopolysaccharide, or LPS, associated with the outer membrane of Gram-negative bacteria. LPS does not have to arrive attached to a living cell. FDA states that sterilizing-grade filtration and moist-heat sterilization have not been shown effective at removing endotoxin. A material can therefore pass a test for recoverable microbes and still warrant a separate endotoxin measurement.²

These are complementary measurements, not two names for the same quality attribute. An analytical report should identify which one was performed and on what material.

2. What an endotoxin method actually reads

Traditional Limulus amebocyte lysate (LAL) methods use a reaction cascade from horseshoe-crab blood cells. Depending on the format, the laboratory reads a gel clot, turbidity, or color change. Recombinant factor C (rFC) uses a manufactured form of the endotoxin-sensing protein instead of animal-derived lysate. USP <86> also describes recombinant cascade reagents, with fluorescent or color-based detection. Both approaches are designed to detect bacterial endotoxins from Gram-negative organisms.³⁴

Method choice is only part of the result. FDA guidance says a method comparison should assess detection limits, inhibition or enhancement, and the response of spiked product samples.³ An endotoxin result should not be described as “pyrogen-free”: an endotoxin-specific assay does not cover every possible fever-producing substance. FDA explicitly treats non-endotoxin pyrogens as a separate analytical concern.³

3. The peptide matrix can change the answer

An endotoxin assay measures a signal in a particular sample matrix, not in a vacuum. Peptide charge and structure, pH, salts, proteins, surfactants, and other components may suppress or enhance a test response. This is more than a theoretical caution: Bhunia and colleagues showed that several designed LPS-binding peptides inhibited LPS-mediated activation in a chromogenic LAL assay. Their result demonstrates a possible mechanism for under-recovery; it does not mean every peptide behaves that way.⁵

The practical check is a positive product control. A laboratory adds a known endotoxin amount to an aliquot of the actual sample, then compares its recovery with the expected response. Recovery outside the method’s accepted range signals inhibition or enhancement at that tested concentration. The laboratory may assess a suitable dilution, but over-dilution can put a meaningful signal below detection; FDA advises finding the lowest dilution that neutralizes interference rather than treating the maximum valid dilution as the routine choice.³

A defensible report states the method, test dilution, detection or reporting limit, blank controls, and the product-control outcome. “Not detected” means below the validated method’s reporting capability under those conditions. It does not mean a mathematical zero, nor does it rescue an assay whose matrix control failed.

4. Keep the units attached to the experiment

Endotoxin units (EU) are reported relative to a calibrated reference standard, not as a count of bacterial cells. An EU/mg result describes endotoxin per mass of tested material; EU/mL describes a concentration in a prepared solution; and EU/container describes a total amount associated with one container. These numbers cannot be compared without the sample mass, solution concentration, and preparation details. FDA’s guidance discusses reference-standard calibration and product-specific limits rather than a universal number for every material.³

For a defined in-vitro setup: peptide-associated EU/mL = reported EU/mg × peptide concentration in mg/mL. This unit conversion excludes endotoxin contributed by medium, water, and other reagents.

The concentration at the point of cell exposure is more informative than a number detached from the experiment. In one human T-cell immunogenicity assay, Jeong and colleagues found that endotoxin in a biotherapeutic test material altered cell-proliferation and CD14-positive myeloid-cell readouts, creating a potential false-positive interpretation.⁶ That study is evidence of an assay-confounding pathway, not a universal endotoxin cutoff for research peptides. Cell type, endpoint, matrix, and exposure conditions all matter.

5. An evidence checklist for the lab record

Before interpreting a peptide experiment, ask what the documentation actually supports:

• ☐ Is the test result linked to the exact material or lot under study, with the specimen form and test date stated?
• ☐ Is the endotoxin method named, including LAL or recombinant format and its readout?
• ☐ Are the result, denominator, detection or reporting limit, and tested dilution all visible?
• ☐ Was suitability shown in that matrix with an acceptable positive product control and appropriate blanks?
• ☐ If “sterility” is claimed, is there a separate, named microbiological method and a clear description of the sample tested?
• ☐ Have the research team’s medium, water, and other input controls been considered alongside the peptide?

A bare “pass” leaves most of these questions unanswered. Good interpretation is specific: describe the method, its validated conditions, and the sampled material, then relate the result to the assay being run. The FDA and USP sources below provide analytical context for regulated testing; they are not evidence that any particular RegeneX lot has undergone these tests or received regulatory approval. This article concerns laboratory research materials only, with no human or animal use implied.

Related reading: How to read a Certificate of Analysis and How to evaluate peptide stability claims.